Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1
NCT01421992Phase 3Completed
- Sponsor
- Université Laval
- Start
- Jun 2008
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylphenidate hydrochloride extended-release chewable tablet in myotonic dystrophy type 1 (DM1), sponsored by Université Laval. Started Jun 2008; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT01421992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421992.